Stephen Brincat

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Antonio C. Wolff, Ann Lazar, Igor Bondarenko et al. · Journal of Clinical Oncology · 2012 · 272 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Natural progesterone and antihypertensive action.

P B Rylance, M Brincat, K. J. Lafferty et al. · BMJ · 1985 · 104 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

Mario Campone, Igor Bondarenko, Stephen Brincat et al. · Annals of Oncology · 2011 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

Charles S. Fuchs, Josep Tabernero, Jiří Tomášek et al. · British Journal of Cancer · 2016 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17